Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-09-18 Major Shareholding Noti…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in CANTARGIA AB. It explicitly mentions 'Reason for major shareholding notification' and provides the 'Resulting distribution of total holdings' with percentages crossing a threshold (5%). This structure is characteristic of a Major Shareholding Notification, which corresponds to the code MRQ.
2023-09-18 English
Cantargia announces new nadunolimab clinical trial in leukemia financed by external US grant
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia announcing a new clinical trial for their drug nadunolimab, funded by a US Department of Defense grant. It details the nature of the trial, the medical context of the diseases (AML/MDS), and provides contact information. It does not fit into specific financial reporting categories like 10-K, IR, or CT, and is not a report publication announcement (RPA) as it is the primary announcement itself. Therefore, it falls under the general regulatory filing/announcement category.
2023-09-18 English
Cantargia meddelar ny klinisk studie med nadunolimab inom leukemi finansierad av externt amerikanskt anslag
Capital/Financing Update Classification · 95% confidence The document is a press release from Cantargia AB announcing that they have been awarded a \$1.1 million grant from the US Department of Defense to fund a clinical Phase Ib/IIa study for their drug candidate, nadunolimab, in patients with MDS or AML. This announcement details new clinical trial activity, funding sources, and scientific background. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since it announces a specific development related to clinical trials and funding, it fits best under Capital/Financing Update (CAP) due to the grant funding, or potentially Regulatory Filings (RNS) as a general corporate announcement. However, the core subject is the *funding* and initiation of a *new clinical study*. Given the options, 'Capital/Financing Update' (CAP) is a strong fit because of the explicit mention of the \$1.1 million grant funding the study. Alternatively, since it is a general corporate announcement about a significant development, 'Regulatory Filings' (RNS) is the standard fallback. Given the specific nature of the announcement focusing on securing external funding for a clinical trial, CAP is more precise than the general RNS fallback. However, many press releases announcing clinical progress or funding are often categorized broadly. Since the text is a full press release and not just a short notice linking to a report, it is not RPA. I will classify this as a Capital/Financing Update (CAP) due to the explicit mention of the grant funding the study, which is a financing activity for the trial's execution.
2023-09-18 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by a specific holder ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension'). It explicitly mentions the 'Reason for major shareholding notification Sell' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' figures for shares and voting rights, culminating in a 'Group total holdings' percentage (5.34525%). This structure is characteristic of a Major Shareholding Notification, where investors must report when their stake crosses certain thresholds. This aligns perfectly with the definition for Major Shareholding Notification (MRQ). The document length is short (3433 chars), but the content is the notification itself, not an announcement of a report.
2023-09-06 English
Cantargia: FDA grants Orphan Drug Designation to CAN10 for treatment of systemic sclerosis
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the FDA has granted Orphan Drug Designation to the company's drug candidate, CAN10. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it is the primary announcement itself. Since it is a general corporate regulatory announcement regarding company operations and drug development status, it falls under the 'Regulatory Filings' (RNS) category.
2023-09-06 English
Cantargia: FDA beviljar särläkemedelsstatus (Orphan Drug Designation) till CAN10 för behandling av systemisk skleros
Regulatory Filings Classification · 100% confidence The document is a press release from Cantargia announcing that the FDA granted Orphan Drug Designation (särläkemedelsstatus) to their drug candidate CAN10 for treating systemic sclerosis. The text includes key highlights, management commentary, and a concluding statement referencing EU Market Abuse Regulation and providing contact information. Crucially, the document ends with a section titled 'Bifogade filer' (Attached files) which links to a PDF of the announcement itself. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces that a report/filing is attached or published, it should be classified as a Report Publication Announcement (RPA) rather than the underlying report (like an ER or 10-K). Since this is a formal announcement about a regulatory event (FDA designation) and points to the full document, RPA is the most appropriate classification, although RNS (Regulatory Filings) is a close secondary option. Given the structure typical of a press release announcing a specific event/document release, RPA is selected.
2023-09-06 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.